Compare Abbott Laboratories (ABT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vertex Pharmaceuticals Incorporated — how do they compare? Abbott Laboratories trades at $109.69 (market cap $187.95B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ABT | VRTX | |
|---|---|---|
Market Cap | $187.95B | $132.79B |
Sector | Health | Health |
52-Week High | $136.62 | $529.65 |
52-Week Low | $82.57 | $376.62 |
Enterprise Value | $214.96B | $126.92B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
